Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
10592studies shown
Showing 8,785-8,796 of 10,592
Drug study icon
CompletedNCT00697515

Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

This study exists to compare options and see whether the medication Lisdexamfetamine offers something meaningfully different. Researchers are trying to understand what the medication Lisdexamfetamine could change in day-to-day care and decision-making.

In United States
ADHDDrugA study involving a medication or substance.From 18 Years to 55 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
Drug study icon
CompletedNCT00280566

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolarity type I (Manic or Mixed)

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.

In United States
BipolarityDrugOver 18 Years
Countries
United States, France, Chile, ...
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition
Bipolarity
Drug study icon
CompletedNCT02411526

Safety and PK study With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

This study exists to better understand the safety of a digital app or remote support tool and how manageable it feels in practice. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

Remote / online
SchizophreniaDrugFrom 18 Years to 60 Years
Countries
United States
Sponsor
Zogenix, Inc.
Condition
Schizophrenia
Drug study icon
TerminatedNCT01122927

Safety study of aripiprazole in schizophrenia

This study was terminated in the United States, in Bulgaria, in Croatia, .... It is testing aripiprazole for schizophrenia.

In United States
Bipolarity, SchizophreniaDrugFrom 10 Years to 17 Years
Countries
United States, Bulgaria, Croatia, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Bipolarity, Schizophrenia
Drug study icon
CompletedNCT01892384

Safety and Tolerability of BI 409306 in people with Schizophrenia

This study exists to better understand the safety of a medication treatment and how manageable it feels in practice. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

In United States
SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
Drug study icon
CompletedNCT03238326

Open-Label Flexible-dose Brexpiprazole for schizophrenia

This study is completed in the United States, in France, in Italy, .... It is testing Open-Label Flexible-dose Brexpiprazole for schizophrenia.

In United States
SchizophreniaDrugFrom 13 Years to 17 Years
Countries
United States, France, Italy, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT02773576

Safety and Tolerability of Risperidone Implants

This summary needs review. Please check the official study record and contact the research team for details.

In United States
SchizophreniaDrugFrom 18 Years to 70 Years
Countries
United States
Sponsor
Braeburn Pharmaceuticals
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.